Biogen (BIIB) PT Lowered to $310 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $254.46 --0%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $310.00 (from $325.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Choice Hotels (CHH) PT Raised to $130 at Freedom Broker
- Sight Sciences Inc. (SGHT) PT Raised to $14 at Lake Street
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
